BioGaia AB (publ) (BGLAF)

Market Cap	1.20B +7.9%
Revenue (ttm)	163.08M +9.8%
Net Income	35.83M +21.1%
EPS	0.35 +21.3%
Shares Out	n/a
PE Ratio	33.47
Forward PE	26.65
Dividend	0.43 (3.76%)
Ex-Dividend Date	May 8, 2026

Volume	100
Open	11.55
Previous Close	12.20
Day's Range	11.55 - 11.55
52-Week Range	10.24 - 12.20
Beta	0.32
Analysts	n/a
Price Target	n/a
Earnings Date	Feb 12, 2027

About BioGaia AB

BioGaia AB (publ), a healthcare company, develops, manufactures, markets and sells probiotic products for gut, oral, and immune health in Europe, the Middle East, Africa, the United States, the Asia-Pacific, Australia, and New Zealand. It operates through Pediatrics, Adult Health, and Other segments. The Pediatrics segment offers drops, oral rehydration solutions, and gut health tablets, as well as cultures that are used as an ingredient in infant formula and milk formula. Its Adult Health segment provides gut health tablets, bone health tablet...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1990
• Employees: 251
• Stock Exchange: OTCMKTS
• Ticker Symbol: BGLAF

Financial Performance

In 2025, BioGaia AB's revenue was 1.54 billion, an increase of 8.11% compared to the previous year's 1.42 billion. Earnings were 332.76 million, a decrease of -5.30%.

Financial numbers in SEK

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Sep 5, 2026

Data Sources Report a data error